LA MARCA, Antonio
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 26.317
AS - Asia 9.178
EU - Europa 8.711
SA - Sud America 1.716
AF - Africa 182
OC - Oceania 74
Continente sconosciuto - Info sul continente non disponibili 15
Totale 46.193
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 26.056
SG - Singapore 3.080
GB - Regno Unito 2.729
CN - Cina 2.291
HK - Hong Kong 1.774
BR - Brasile 1.383
IT - Italia 1.337
SE - Svezia 1.117
DE - Germania 810
VN - Vietnam 655
FI - Finlandia 632
UA - Ucraina 578
RU - Federazione Russa 490
TR - Turchia 396
BG - Bulgaria 240
FR - Francia 167
KR - Corea 166
IN - India 152
ID - Indonesia 148
AR - Argentina 144
CA - Canada 129
NL - Olanda 105
JP - Giappone 88
MX - Messico 87
ES - Italia 83
ZA - Sudafrica 62
IQ - Iraq 59
RO - Romania 58
EC - Ecuador 57
PL - Polonia 56
AU - Australia 54
IR - Iran 51
BD - Bangladesh 47
IE - Irlanda 41
PK - Pakistan 41
LT - Lituania 36
CO - Colombia 34
CZ - Repubblica Ceca 30
BE - Belgio 29
AT - Austria 28
PH - Filippine 28
CL - Cile 27
UZ - Uzbekistan 27
MY - Malesia 24
PY - Paraguay 23
VE - Venezuela 23
EG - Egitto 21
MA - Marocco 21
CH - Svizzera 20
DZ - Algeria 20
DK - Danimarca 17
NZ - Nuova Zelanda 17
AE - Emirati Arabi Uniti 15
AL - Albania 15
KE - Kenya 15
TH - Thailandia 15
HR - Croazia 13
TW - Taiwan 13
IL - Israele 12
PE - Perù 12
SA - Arabia Saudita 12
JO - Giordania 11
KZ - Kazakistan 11
NO - Norvegia 11
LV - Lettonia 10
TN - Tunisia 10
CR - Costa Rica 9
DO - Repubblica Dominicana 9
GR - Grecia 9
MD - Moldavia 9
NP - Nepal 9
AZ - Azerbaigian 7
EU - Europa 7
HU - Ungheria 7
NG - Nigeria 7
PA - Panama 6
PT - Portogallo 6
AM - Armenia 5
BO - Bolivia 5
HN - Honduras 5
PS - Palestinian Territory 5
SC - Seychelles 5
SK - Slovacchia (Repubblica Slovacca) 5
UY - Uruguay 5
A2 - ???statistics.table.value.countryCode.A2??? 4
BA - Bosnia-Erzegovina 4
GH - Ghana 4
KW - Kuwait 4
LB - Libano 4
MN - Mongolia 4
RS - Serbia 4
SI - Slovenia 4
SN - Senegal 4
ET - Etiopia 3
GT - Guatemala 3
JM - Giamaica 3
MK - Macedonia 3
PR - Porto Rico 3
XK - ???statistics.table.value.countryCode.XK??? 3
BB - Barbados 2
Totale 46.139
Salva come PNG Salva come JPEG
Città #
Fairfield 3.903
Ashburn 2.484
Santa Clara 2.204
Singapore 1.905
Woodbridge 1.886
Hong Kong 1.747
Southend 1.737
Houston 1.575
Seattle 1.470
Cambridge 1.304
Wilmington 1.171
Chandler 1.125
Jacksonville 900
Ann Arbor 758
Dearborn 681
Nyköping 675
London 611
Hefei 590
Helsinki 525
Beijing 493
Modena 389
Chicago 330
Los Angeles 321
San Diego 288
Ho Chi Minh City 254
Princeton 237
Sofia 234
Izmir 206
New York 202
Eugene 193
San Jose 187
The Dalles 176
Moscow 175
Boardman 160
Seoul 133
Buffalo 130
Shanghai 127
São Paulo 127
Bremen 119
Hanoi 117
Jakarta 108
Salt Lake City 108
Council Bluffs 98
Dallas 89
Munich 87
Milan 77
Redwood City 68
Tampa 68
Redondo Beach 65
Rome 63
Bologna 61
Tokyo 56
Guangzhou 55
Amsterdam 52
Columbus 50
Rio de Janeiro 47
Elk Grove Village 43
Frankfurt am Main 43
Phoenix 42
Toronto 42
Falls Church 40
Warsaw 39
Johannesburg 38
Norwalk 37
Atlanta 36
Dublin 36
Denver 35
Kilburn 34
Stockholm 34
Montreal 33
Nanjing 33
Fremont 32
Melbourne 32
Brooklyn 31
Iasi 31
Belo Horizonte 27
Turku 27
Kunming 26
Mexico City 26
Brasília 25
Ankara 24
Haiphong 24
Jinan 24
Parma 24
San Francisco 24
Tashkent 24
Augusta 23
Boston 23
Nuremberg 23
Orem 23
Salvador 23
Dulles 22
Biên Hòa 21
Chennai 21
Da Nang 21
Philadelphia 21
Porto Alegre 21
Dong Ket 20
Fuzhou 20
Newark 20
Totale 34.269
Salva come PNG Salva come JPEG
Nome #
Individualized versus conventional ovarian stimulation for in vitro fertilization: a multicenter, randomized, controlled, assessor-blinded, phase 3 noninferiority trial 585
Anti-Mullerian hormone (AMH): what do we still need to know? 433
Anti-Mullerian hormone (AMH) as a predictive marker in assisted reproductive technology (ART). 413
MATER protein as substrate of PKCepsilon in human cumulus cells. 388
LH and hCG Action on the Same Receptor Results in Quantitatively and Qualitatively Different Intracellular Signalling 341
Chronic endometritis in recurrent implantation failure: Use of prednisone and IVF outcome 326
Age-specific nomogram for the decline in antral follicle count throughout the reproductive period 314
Vitamin D and ovarian reserve: making clinical decisions 300
The anti-Müllerian hormone (AMH) acts as a gatekeeper of ovarian steroidogenesis inhibiting the granulosa cell response to both FSH and LH 300
Embryo quality and implantation rate in two different culture media: ISM1 versus Universal IVF Medium. 296
From a circle to a sphere: the ultrasound imaging of ovarian follicle with 2D and 3D technology 296
Individualization of controlled ovarian stimulation in IVF using ovarian reserve markers: from theory to practice 294
Added value of ovarian reserve testing on patient characteristics in the prediction of ovarian response and ongoing pregnancy: An individual patient data approach 294
The menstrual cycle regularization following d-chiro-inositol treatment in PCOS women: a retrospective study 289
FSHR polymorphism p.N680S mediates different responses to FSH in vitro 288
Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV 287
Human ovarian tissue cryopreservation: effect of sucrose concentration on morphological features after thawing 285
Evidence for expression and functionality of FSH and LH/hCG receptors in human endometrium 285
Anti-Mullerian hormone (AMH) in female reproduction: is measurement of circulating AMH a useful tool? 282
Modulation of gonadotrophin induced steroidogenic enzymes in granulosa cells by d-chiroinositol 282
Gene expression profiles of human granulosa cells treated with bioequivalent doses of corifollitropin alfa (CFA) or recombinant human follicle-stimulating hormone (recFSH) 278
Female age, serum antimüllerian hormone level, and number of oocytes affect the rate and number of euploid blastocysts in in vitro fertilization/intracytoplasmic sperm injection cycles 277
A novel transnational fresh oocyte donation (TOD) program based on transport of frozen sperm and embryos 277
How Much Does AMH Really Vary in Normal Women? 272
Age-specific reference values for serum FSH and estradiol levels throughout the reproductive period 268
Development of a nomogram based on markers of ovarian reserve for the individualisation of the follicle-stimulating hormone starting dose in in vitro fertilisation cycles 266
Elevated levels of nitrous dioxide are associated with lower AMH levels: A real-world analysis 266
Individualization of the FSH starting dose in IVF/ICSI cycles using the antral follicle count 265
Anti-Mullerian hormone measurement on any day of the menstrual cycle strongly predicts ovarian response in assisted reproductive technology 264
Polymorphisms in gonadotropin and gonadotropin receptor genes as markers of ovarian reserve and response in in vitro fertilization 263
Reference values in ovarian response to controlled ovarian stimulation throughout the reproductive period 262
Periodontal disease and nitric oxide levels in low risk women with preterm labor 261
Adnexal torsion during pregnancy after oocyte in vitro maturation and intracytoplasmic sperminjection cycle 260
New strategies of ovarian stimulation based on the concept of ovarian follicular waves: From conventional to random and double stimulation 259
Evidence for cycle-dependent expression of follicle-stimulating hormone receptor in human endometrium 258
Age-related normograms of serum antimüllerian hormone levels in a population of infertile women: a multicenter study 256
The anti-Müllerian hormone (AMH) induces forkhead box L2 (FOXL2) expression in primary culture of human granulosa cells in vitro 255
Nitric Oxide concentration in endometrial washing throughout the menstrual cycle 252
Utero-vaginal anastomosis in the treatment of cervical atresia 252
The ovarian response to controlled stimulation in IVF cycles may be predictive of the age at menopause 249
Primary ovarian insufficiency: autoimmune causes. 247
Live birth rates in the different combinations of the Bologna criteria poor ovarian responders: a validation study 247
A randomized controlled trial investigating the use of a predictive nomogram for the selection of the FSH starting dose in IVF/ICSI cycles 247
Seminal plasma total antioxidant capacity and semen parameters in patients with varicocele 245
Membrane Estrogen Receptor (GPER) and Follicle-Stimulating Hormone Receptor (FSHR) Heteromeric Complexes Promote Human Ovarian Follicle Survival 244
Prediction of age at menopause from assessment of ovarian reserve may be improved by using body mass index and smoking status. 243
Corrigendum to “Premature ovarian senescence and a high miscarriage rate impair fertility in women with HCV” [J Hepatol 68 (2018) 33–41](S0168827817322596)(10.1016/j.jhep.2017.08.019) 243
Does plasma insulin level affect ovarian response to exogenous administration of follicle-stimulating hormone in women without polycystic ovary syndrome? 240
Ovarian response markers lead to appropriate and effective use of corifollitropin alpha in assisted reproduction 239
Anti-Mullerian hormone concentrations in maternal serum during pregnancy 238
Administration of L-thyroxine does not improve the response of the hypothalamo-pituitary-ovarian axis to clomiphene citrate in functional hypothalamic amenorrhea 237
Effects of metformin on adrenal steroidogenesis in women with polycystic ovary syndrome 235
Adrenal adenocarcinoma and empty sella syndrome in a 37-year-old woman 234
ESHRE consensus on the definition of 'poor response' to ovarian stimulation for in vitro fertilization: the Bologna criteria 233
Increased risk of preterm birth and low birthweight with very high number of oocytes following IVF: an analysis of 65 868 singleton live birth outcomes 233
Pregnant woman infected by Coronavirus disease (COVID-19) and calcifications of the fetal bowel and gallbladder 233
Rectovaginal fistula repair using fascia graft of autologous abdominal muscles 232
Anti-Müllerian hormone-based prediction model for a live birth in assisted reproduction 231
Anti-Mullerian hormone plasma levels in spontaneous menstrual cycle and during treatment with FSH to induce ovulation 230
How to personalize ovarian stimulation in clinical practice 228
The ovarian follicular pool and reproductive outcome in women. 227
Administration of somatostatin analogue reduces uterine and myoma volume in women with uterine leiomyomata 226
8th World Congress of Gynecological Endocrinology 225
Prediction of an excessive response in in vitro fertilization from patient characteristics and ovarian reserve tests and comparison in subgroups: An individual patient data meta-analysis 225
Evaluation of the treatment with D-chiroinositol on levels of oxidative stress in PCOS patients 224
The use of ovarian reserve markers in IVF clinical practice: a national consensus 223
Rectus abdominis muscle endometriosis: Case report and review of the literature 222
The combination of genetic variants of the FSHB and FSHR genes affects serum FSH in women of reproductive age 221
External validation of anti-Müllerian hormone based prediction of live birth in assisted conception 220
Soluble L-selectin levels during controlled ovarian hyperstimulation 220
Individualised gonadotropin dose selection using markers of ovarian reserve for women undergoing in vitro fertilisation plus intracytoplasmic sperm injection (IVF/ICSI) 219
Normal serum anti-Müllerian hormone levels in the general female population and the relationship with reproductive history 218
The management of vaginal agenesis: report of 104 cases 217
The physiology and clinical utility of anti-Mullerian hormone in women 216
Metformin treatment of PCOS during adolescence and the reproductive period 214
Endocrine and metabolic effects of octreotide, a somatostatin analogue, in lean PCOS patients with either hyperinsulinaemia or lean normoinsulinaemia 214
Anti-mullerian hormone in premenopausal women and after spontaneous or surgically induced menopause 214
The FSHR polymorphism p.N680S mediates different response kinetics to FSH in vitro 214
Clomiphene citrate increases insulin-like growth factor binding protein-1 and reduces insulin-like growth factor-I without correcting insulin resistance associated with polycystic ovarian syndrome 213
Thyroid function in early pregnancy II: Paradoxical growth hormone response to thyrotropin-releasing hormone 213
Advances in the Molecular Pathophysiology, Genetics, and Treatment of Primary Ovarian Insufficiency 213
Reply: The two sides of the individualization of controlled ovarian stimulation 212
Clinical application of a nomogram based on age, serum FSH and AMH to select the FSH starting dose in IVF/ICSI cycles: a retrospective two-centres study 212
Hormonal and ultrasound markers of ovarian function in a woman with a balanced 1;11 translocation 210
Surgical treatment of ovarian dermoid cysts 209
Gestrinone in the treatment of uterine leiomyomata: effects on uterine blood supply 208
Short-term treatment of uterine fibromyomas with danazol 208
Progestin effects on epidermal growth factor receptor (EGFR) endometrial expression in normal and hyperplastic endometrium 207
Veralipride administered in combination with raloxifene decreases hot flushes and improves bone density in early postmenopausal women 207
Pyrexia, leukocytosis and elevated circulating platelets associated to uterine stromal sarcoma with rhabdoid differentiation 205
Recombinant human leptin in women with hypothalamic amenorrhea. 204
Recombinant LH administration in subsequent cycle after "unexpected" poor response to recombinant FSH monotherapy 204
Possibilities and Limits of Ovarian Reserve Testing in ART 203
Whatever its variability, antimüllerian hormone remains the most stable hormonal predictor 202
Effects of the insulin sensitizer pioglitazone on menstrual irregularity, insulin resistance and hyperandrogenism in young women with polycystic ovary syndrome 202
Evaluation of plasma levels of renin-aldosterone and blood pressure in women over 35 years treated with new oral contraceptives 202
Antimüllerian hormone in gonadotropin releasing-hormone antagonist cycles: prediction of ovarian response and cumulative treatment outcome in good-prognosis patients 201
Effects of metformin on gonadotropin-induced ovulation in women with polycystic ovary syndrome 201
Effects of estradiol alone or in combination with cyproterone acetate on carotid artery pulsatility index in postmenopausal women 201
Anti-Müllerian hormone: clairvoyance or crystal clear? 200
Totale 25.093
Salva come PNG Salva come JPEG
Categoria #
all - tutte 198.082
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 198.082
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/20213.027 0 0 0 0 0 0 570 871 261 699 353 273
2021/20224.566 176 862 513 160 84 175 345 216 415 356 872 392
2022/20233.625 454 416 349 293 473 434 82 308 414 39 174 189
2023/20243.007 95 153 122 270 479 180 510 456 68 95 131 448
2024/20258.209 260 89 107 581 1.510 1.099 434 449 1.158 519 786 1.217
2025/20269.254 1.057 530 1.581 2.000 2.208 1.427 451 0 0 0 0 0
Totale 46.626